A cost-cutting push unveiled Friday by the Swiss drug maker Roche Holding AG, which last year paid $46.8 billion for the US biotechnology giant Genentech Inc., has raised fresh questions about the fate of Genzyme Corp., a Cambridge biotech.
boston